Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.38 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in hepatocytes | 0.75 |
| chemistry Open Targets | compounds already reach it: phentolamine mesylate, norepinephrine, phentolamine +63 | 1.00 |
| trials ClinicalTrials.gov | 44 Parkinson's trials, 7 stopped | 0.87 |
| literature PubMed | 2 Parkinson's papers of 185 | 0.85 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 0688
Sealed predictions
- ADRA1A in dopamine neurons, braak+0.74 (p 0.024) → +0.37 (p 0.334)receipt 0696
- ADRA1A in oligodendrocytes, braak-0.05 (p 0.893) → -0.44 (p 0.237)receipt 0695
Swarm cases
receipt 0696: ADRA1A in dopamine neurons, braak
- power
- full sample +0.52 (p 0.027, n 18), 95% CI +0.07 to +0.79. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.52 (p 0.027, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.55 (p 0.018, n 18). not the mix.
- skeptic
- leave-one-out range +0.46 to +0.64, sign flips 0; without severely affected donors +0.52 (p 0.027, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ADRA1A in dopamine neurons.
case closed: nothing better to follow up.
receipt 0695: ADRA1A in oligodendrocytes, braak
- power
- full sample -0.21 (p 0.393, n 18), 95% CI -0.62 to +0.28. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.26 (p 0.302, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.15 (p 0.549, n 18). could be the mix.
- skeptic
- leave-one-out range -0.33 to -0.11, sign flips 0; without severely affected donors -0.21 (p 0.393, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ADRA1A in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts